Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to lower adverse Events grade 3‐4 compared with chemotherapy (low certainty).
1 finding from 1 review
QoL · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to higher QOL‐C30 GHS/QOL (range 0‐100) ‐ change from baseline to week 15 compared with chemotherapy (low certainty).
1 finding from 1 review
Overall survival (OS) · People with advanced non‐small cell lung cancer
Combined immune checkpoint inhibitors (ICIs) probably leads to lower overall Survival (OS) compared with chemotherapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate (OSR) · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer
Combined immune checkpoint inhibitors (ICIs) showed no clear difference in adverse Events grade 3 to 4 compared with chemotherapy (low certainty).
1 finding from 1 review
All‐cause mortality · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP leads to lower mortality compared with chemotherapy including ABVD (high certainty).
1 finding from 1 review
Relapse, progression or death (calculated instead of PFS) · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP probably leads to lower progression, relapse or death compared with chemotherapy including ABVD (moderate certainty).
1 finding from 1 review
Adverse event: treatment‐related mortality · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP showed no clear difference in adverse event: treatment‐related mortality compared with chemotherapy including ABVD (low certainty).
1 finding from 1 review
Adverse event: secondary malignancies · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP showed no clear difference in adverse event: secondary malignancies compared with chemotherapy including ABVD (low certainty).
1 finding from 1 review
Adverse event: secondary malignancies: AML or MDS · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP may leads to higher adverse event: secondary malignancies: AML or MDS compared with chemotherapy including ABVD (low certainty).
1 finding from 1 review
Adverse event: infertility (secondary amenorrhoea) · Patients with early unfavourable or advanced stage HL
It is very uncertain whether escalated BEACOPP changes adverse event: infertility (secondary amenorrhoea) compared with chemotherapy including ABVD (very low certainty).
1 finding from 1 review
Quality of life · Patients with early unfavourable or advanced stage HL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to death from any cause Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors showed no clear difference in time to death from any cause Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review
Health‐related quality of life · participants with advanced or metastatic muscle invasive bladder cancer
1 finding from 1 review
Adverse events grade 3 to 5 Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors probably leads to lower adverse events grade 3 to 5 Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review
Time to death from bladder cancer · participants with advanced or metastatic muscle invasive bladder cancer
1 finding from 1 review
Time to progression · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors probably leads to higher time to disease progression Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors showed no clear difference in discontinuation due to adverse events Range of compared with any first‐line chemotherapy (low certainty).
1 finding from 1 review
Overall survival · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy
EGFR tyrosine kinase inhibitor (TKI) showed no clear difference in overall survival compared with observation alone (low certainty).
1 finding from 1 review